Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Penumbra's change in receivables for the quarter that ended in Jun. 2026 was MXN-140 Mil. It means Penumbra's Accounts Receivable
increased by MXN140 Mil
from Mar. 2026 to Jun. 2026 .
Penumbra's change in receivables for the fiscal year that ended in Dec. 2025 was MXN-351 Mil. It means Penumbra's Accounts Receivable
increased by MXN351 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Penumbra's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 44.55.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Penumbra's liquidation value for the
three
months ended in Jun. 2026 was MXN10,102 Mil.
Penumbra (MEX:PEN) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Penumbra's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Penumbra Change In Receivables Related Terms
Penumbra Change In Receivables Historical Data
* Premium members only.
The historical data trend for Penumbra's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-318 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of MXN-318 Mil mean?
Penumbra (MEX:PEN) has a Change In Receivables of MXN-318 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Penumbra and its competitors.
Is Penumbra's Change In Receivables too high?
Penumbra's current Change In Receivables is MXN-318 Mil. Overall, Penumbra has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Change In Receivables compare to PODD and GMED?
Penumbra's Change In Receivables of MXN-318 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Penumbra and its competitors. Penumbra's current Change In Receivables is MXN-318 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Penumbra (MEX:PEN) has a current Change In Receivables of MXN-318 Mil. The stock's GF Value™ is MXN4,995.95, compared to a current price of MXN4,775.70 — trading 4.4% below its estimated fair value. The current Change In Receivables is MXN-318 Mil. Penumbra's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Penumbra (MEX:PEN), the current Change In Receivables is MXN-318 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (MEX:PEN) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of MXN4,775.70 is trading 4.4% below its estimated GF Value™ of MXN4,995.95.
Key valuation signals for MEX:PEN:
Change In Receivables: MXN-318 Mil
GF Value™: MXN4,995.95 vs. price of MXN4,775.70 (4.4% below fair value)
No single metric tells the full story. See the MEX:PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
88GF Score
Get the complete analysis for MEX:PEN
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PEN has been successfully added to your 
